Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases

IntroductionIxekizumab is a biologic agent primarily indicated for the treatment of moderate to-severe plaque psoriasis. This study aimed to evaluate the post-marketing safety profile of ixekizumab by analyzing adverse event (AE) reports retrieved from the Food and Drug Administration Adverse Event...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Kaidi Zhao, Xuanfeng Tan, Miao Qin, Qinxiao Li, Qinqin Meng, Ying Liu, Jing Li, Jiashu Liu
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Frontiers Media S.A. 2025-10-01
Sarja:	Frontiers in Medicine
Aiheet:	ixekizumab biologics psoriasis FAERS disproportionality analysis adverse events
Linkit:	https://www.frontiersin.org/articles/10.3389/fmed.2025.1652401/full
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!